ZOSTAVAX™
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Herpes Zoster
Conditions
Herpes Zoster, Shingles
Trial Timeline
May 15, 2012 → Oct 16, 2020
NCT ID
NCT01600079About ZOSTAVAX™
ZOSTAVAX™ is a pre-clinical stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT01600079. Target conditions include Herpes Zoster, Shingles.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01600079 | Pre-clinical | Completed |
Competing Products
20 competing products in Herpes Zoster